Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]
A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas ha…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs
A completed clinical trial evaluating a multidisciplinary care program to ensure medication therapy for hematology patients receiving inject…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update notes that EX103 is being studied in a Phase 1/2 trial for relapsed or refractory CD20-positive non-Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: IIT2020-20-SHIRAZIP-WALK: Nature Walks [NA]
The IIT2020-20-SHIRAZIP-WALK trial sponsored by Cedars-Sinai Medical Center has completed, studying breast cancer and several hematologic ma…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: PTCy and ATG for MSD and MUD Transplants [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating post-transplant cyclophosphamide and anti-thymocyte globulin for matched sibling and matched unr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ICP-490 for relapsed or refractory non-Hodgkin lymphoma; the study status is NOT_YET_RECRUITING.
-
CLINICAL_TRIALS withdrawal · 2025-02-25Clinical Trial Update: Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) [Phase 1, Phase 2]
Dizal Pharmaceuticals has withdrawn the Phase 1/2 trial of the oral BTK inhibitor DZD9008 in non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) [Phase 1]
Phase 1 trial evaluating LMP-, BARF1-, and EBNA1-specific cytotoxic T cells for EBV-positive lymphomas; Hodgkin and Non-Hodgkin lymphoma inc…
-
CLINICAL_TRIALS withdrawal · 2025-02-24Clinical Trial Update: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL [Phase 1, Phase 2]
The QUILT-3.052 trial evaluating the NANT Non-Hodgkin Lymphoma Vaccine in relapsed CD20-positive NHL has been withdrawn (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating DZD8586 in relapsed or refractory B-cell non-Hodgkin lymphoma (TAI-SHAN1).
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers [Phase 1]
This is a completed Phase 1 safety study of navitoclax (ABT-263) in combination with rituximab for CD20-positive lymphoid malignancies, incl…
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating chidamide in combination with linperlisib for refractory/relapsed follicular lymphoma is currently recruit…
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL [Phase 1]
Phase 1 study update for ONO-7018 in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia, assessing safety, tolerabili…
-
CLINICAL_TRIALS other · 2025-02-18Clinical Trial Update: A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 clinical trial update for ONO-7018 in relapsed or refractory Non-Hodgkin lymphoma; the study is currently active but not r…
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) [Phase 1, Phase 2]
A clinical trial update indicates the Phase 1/2 study of KB-0742 in relapsed or refractory solid tumors, including platinum-resistant high-g…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma [Phase 2, Phase 3]
A Phase 2/3 clinical trial of NKTR-255 after CD19-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies [Phase 1, Phase 2]
A first-in-human study of the investigational agent 1A46 in advanced CD20/CD19-positive B-cell hematologic malignancies has been terminated;…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford [NA]
Stanford’s clinical trial seeks to evaluate long-term cognitive, neuropsychiatric, and functional outcomes in adults treated with CAR-T ther…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: DS-3201b in Participants With Lymphomas [Phase 1]
Phase 1 clinical trial update for DS-3201b in participants with lymphoma, including non-Hodgkin lymphoma. The study is active but not recrui…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase II trial of CNCT19 cell therapy for relapsed or refractory Non-Hodgkin's lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma [Phase 1]
A terminated Phase 1 trial from Stanford evaluated the PET imaging tracer 18F-F-AraG to assess immunological response to CAR T cell therapy …
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL [Phase 1, Phase 2]
Phase 1/2 trial evaluating anti-CD19 CAR T cells in pediatric patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-H…
-
CLINICAL_TRIALS other · 2025-02-04Clinical Trial Update: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation [Phase 3]
A Phase 3 trial evaluating AB-205 in lymphoma patients undergoing autologous hematopoietic cell transplantation was terminated.
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating siltuximab to prevent CAR T cell–related cytokine release syndrome in CD19-positive non-Hodgkin lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients [Phase 2, Phase 3]
Completed Phase 2/Phase 3 trial evaluating nivolumab with gemcitabine, oxaliplatin, and rituximab in elderly patients with relapsed/refracto…